in Newswire Published on April 14, 2021

CytoDyn Hit with Securities Class Action Over Alleged ‘Hyping’ of HIV Therapy as Potential COVID-19 Treatment

Goodwin v. CytoDyn, Inc. et al.

Filed: April 9, 2021 § 3:21-cv-05260

CytoDyn and its CEO and CFO face a class action over what investors call the biotech company’s “aggressive” hyping of its potential HIV therapy Leronlimab as a possible treatment for COVID-19.

Defendant(s)

CytoDyn, Inc.

State(s)

Washington

Categories

Securities COVID-19

Case Spotlight

Hair Relaxer Lawsuits

ClassAction.org Newsletter

Stay Current

Sign Up For
Our Newsletter

New cases and investigations, settlement deadlines, and news straight to your inbox.

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on April 14, 2021 — 8:18 AM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Senior Managing Editor of ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.